This is simply how it goes. Take a look at the sto

This is simply how it goes. Take a look at the stock price history of any current successful biotech and the only thing to ask is whether or not you wish you would have bought that stock near the lows...

I could complain about the fact that I have all these shares at $3+ basis, $4+ basis, but the reality is that I was hedging against a sudden rise to $10+ and I would have made the same decision every time, fore IPIX's pipeline is out of this world awesome. It's simply a matter of time when that pipeline value gets returned to us shareholders. There's no debt dangers here, the only danger is dilution - a dilution only concern is rare in the pre-revenue emerging biotech world. At worst the industry standard 'toxic' financing comes into play, I'm thinking something is in the works that makes that concern irrelevant (hint: signed termsheet).

Anyway, don't have the bandwidth these days to post often, but figured I'd post my near the lows thoughts. Cheers!